RESIDUAL CARDIOVASCULAR RISK AFTER ISCHEMIC STROKE Risk factors, medication adherence and risk-benefit considerations
Has parts
Paper 1: Gynnild, Mari Nordbø; Aakerøy, Rachel; Spigset, Olav; Askim, Torunn; Beyer, Mona Kristiansen; Ihle-Hansen, Hege; Munthe-Kaas, Ragnhild; Knapskog, Anne Brita; Lydersen, Stian; Næss, Halvor; Røsstad, Tove Garåsen; Seljeseth, Yngve Müller; Thingstad, Pernille; Saltvedt, Ingvild; Ellekjær, Hanne. Vascular risk factor control and adherence to secondary preventive medication after ischaemic stroke. Journal of Internal Medicine 2020 s. 1-14 https://doi.org/10.1111/joim.13161 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (CC BY-NC-ND 4.0)Paper 2: Gynnild, Mari Nordbø; Hageman, Steven HJ; Dorresteijn, Jannick AN; Spigset, Olav; Lydersen, Stian; Wethal, Torgeir; Saltvedt, Ingvild; Visseren, Frank LJ; Ellekjær, Hanne. Risk Stratification in Patients with Ischemic Stroke and Residual Cardiovascular Risk with Current Secondary Prevention. Clinical Epidemiology 2021 ;Volum 13. s. 813-823 https://doi.org/10.2147/CLEP.S322779 This is an open access article under the terms of the Attribution-NonCommercial 3.0 Unported License (CC BY-NC 3.0)
Paper 3: Gynnild, Mari Nordbø; Hageman, Steven HJ; Spigset, Olav; Lydersen, Stian; Saltvedt, Ingvild; Dorresteijn, Jannick AN; Visseren, Frank LJ; Ellekjær, Hanne. Prescription patterns for lipid-lowering therapy after ischemic stroke and expected benefit from intensification of treatment.